Bafna Pharmaceuticals Limited

NSE:BAFNAPH BSE:BAFNAPH

HealthcarePharmaceuticals & Biotechnology

₹378.8

+1.99%1 Oct close

Mkt cap

₹898 Cr

Watch Alert Compare

Quarterly Annual

Year ends (Mar) · % of equity

Holder (%)	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	90.42%	90%	88.3%	75%	75%
	0%	0%	0%	8.53%	9.34%
DII	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%
	9.58%	10%	11.7%	16.47%	15.66%
No. of shareholders	—	—	—	—	6,928

Promoter holding down 15.42 percentage points since Mar 2022. One column per financial year, taken from the register filed at that year end.

2 deals · 6 Aug 2026 – 6 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
6 Aug 2026	M7 GLOBAL FUND PCC-AERION	Bulk	NSE	Sell	6,66,000	₹284.55	₹18.95 Cr
6 Aug 2026	CULLINAN OPPRTS FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1	Bulk	NSE	Buy	6,66,000	₹284.55	₹18.95 Cr

1–2 of 2

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mrs. RAVICHANDRAN CHITRANon-Executive - Independent Director-Chairperson
Ms. SHANMUGAM HEMALATHAExecutive Director
Mr. MAHAVEER CHAND BAFNAChief Executive Officer
Mr. VINAYAK DINESH DENDUKURIExecutive Director
Mrs. AKILA CHINTALAPATI RAJUNon-Executive - Non Independent Director
Mr. UPENDAR MEKALA REDDYNon-Executive - Non Independent Director
Mr. PALAMADAI KRISHNAN SUNDARESANNon-Executive - Independent Director
Mr. Melagiri SridharChief Financial Officer
Mr. A. MohanachandranCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Bafna Pharmaceuticals Limited

Annual record

Bulk & block deals

Board and management